Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    Fixed Dose Combination Products. The Promise and Possibilities

    View: 126

    Website http://bit.ly/2rCZauS | Want to Edit it Edit Freely

    Category cgmp training;compliance in pharma

    Deadline: July 20, 2017 | Date: July 20, 2017

    Venue/Country: New York, U.S.A

    Updated: 2017-06-19 18:29:30 (GMT+9)

    Call For Papers - CFP

    Key Take Away

    An appreciation of

    • Key Drivers from a Patient and Caregiver Perspective

    • Choice of drugs for combination

    • Regulatory considerations

    • Evaluation Programs

    Overview

    Enormous strides have been made over the past decade using combination products to treat viral infections such as HIV and Hepatitis. There has also been an explosion in combination therapy for treating malaria. Possibilities for treating various forms of cancer are also generating excitement. Such developments suggest that combination therapies, based on good clinical rationale, supported by basic Discovery and preclinical research and novel ways of drug delivery could provide a strong rationale for combination drug therapy. The purpose of this Webinar is to introduce the potential and opportunities associated with such developments.

    Why Should You Attend

    Possibilities for Combination Products span a wide range of therapeutic areas and demographics. Aging populations with associated requirements for managing a number of clinical conditions, or where more than one medication is required for a single condition can clearly benefit by reducing “pill burden” and enhancing compliance with the dosing regimen.

    On an unrelated topic, regimens for treating many forms of cancer utilize more than one drug. The same considerations apply to medications for some infectious conditions, especially where chronic dosing is required (eg HIV infection)

    Unit size may compromise swallowing (too-large units due to the presence of more than one drug). Creative strategies to reduce unit size would be expected to enhance compliance as consequently, efficacy

    Awareness of such challenges and ideas for their resolution can enable the assembly of a suitable Target Product Profile for dosage form design. Individuals operating in Business Development and dosage form design and evaluation would benefit from attendance.

    Areas Covered In This Webinar

    The session will cover the full spectrum of considerations such as

    • Strategies driving the development of Combination Products including Life Cycle Management considerations. ii) Opportunities for Intellectual Property,

    • Drug(s) selection,

    • Possibilities for synergized drug delivery,

    • Dealing with drug-drug compatibility issues.

    Patient-related considerations with respect to adherence and compliance will also be discussed as will the evaluation programs required by Regulatory Agencies.

    Learning Objectives

    The objective of this pharmaceutical training is to provide attendees with a comprehensive account of the opportunities, considerations, challenges and programs involved in a variety of Combination Product Development programs.

    Who Will Benefit

    Professionals in Business Development, Marketing, Dosage Form Design, Regulatory Affairs and Project Management.

    For more detail please click on this below link:

    http://bit.ly/2rCZauS

    Email: referralsatatozcompliance.com

    Toll Free: +1- 844-414-1400

    Tel: +1-516-900-5509

    Fax: +1-516-300-1584


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.